Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046

JOHNSON & JOHNSON (JNJ)

304
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : FDA : J&J Unit Recalls Potentially Flammable Bone Putty

08/21/2012 | 06:13pm US/Eastern
   By Ben Fox Rubin 
 

The Food and Drug Administration said Johnson & Johnson (JNJ) unit Synthes last month initiated a recall on certain lots of bone putty, saying the medical product could catch fire during surgery.

The FDA gave the recall a Class I designation, its most serious type of recall.

The regulator said Synthes in early July issued a medical device recall letter, asking medical facilities to examine their inventories and immediately stop using specific lots of the putty. The product, called a hemostatic bone putty, is used to stop bone bleeding by creating a physical barrier along the edges of bones that have been damaged by trauma or cut during surgery.

The FDA said the putty could ignite under some conditions if contacted with certain surgical equipment.

The lots recalled were manufactured between July 6, 2011, and Dec. 14, 2011, and were distributed from Dec. 22, 2011, to June 25, 2012.

J&J in June completed its $19.7 billion purchase of medical-device maker Synthes. The health-care giant has worked to tackle a range of problem products, such as the bottles of children's Tylenol and other popular over-the-counter medicines, as well as some contact lenses and certain hip implants, that the company recalled due to manufacturing problems.

The company's shares closed Tuesday at $67.78 and were up 15 cents after hours. The stock is up 3.4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on JOHNSON & JOHNSON
07/03 Exclusive - Hospira wins French biosimilar drug tender at 45 percent discount
07/03 China's Li Ning says vice-chairman Kim resigns, names new director
07/03 JOHNSON & JOHNSON : Investigational HIV Vaccine Regimen Shows Encouraging Result..
07/02 JOHNSON & JOHNSON : Investigational HIV Vaccine Regimen Shows Encouraging Result..
07/02 GLAXO SMITH KLINE : Statement To Parliament On The Proposed Anti-Ebola Vaccine
07/01 California considering banning biodegradable microbeads from personal care pr..
06/30 JOHNSON & JOHNSON : Talcum Powder Lawsuit News: Ovarian Cancer Allegations Head ..
06/29 XEROX : Johnson & Johnson : overhauls office automation with Oxbow and Bytes Doc..
06/29 JOHNSON & JOHNSON : STELARA® Receives European Commission Approval For Treatment..
06/29 JOHNSON & JOHNSON : Talcum Powder Lawsuit News: Ovarian Cancer Allegations Head ..
Advertisement
Chart
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials